Posts tagged: orgenex biopharma

Vitalwave™ – An Overview

Vitalwave™ is the application of photodisinfection to the birth canal. It is a therapy currently under development by OrGenX Biopharma Corporation and Ondine Biomedical Inc. for the prevention of mother-to-child transmission (PMTCT) of HIV. More than 90% of HIV infections in children are caused by mother-to-child transmission. This is the equivalent of 1,600 children becoming infected with HIV every day, or one child every minute1, affecting 1 out of every 4 babies born. Vitalwave™ is intended to bypass the stigma associated with AIDS, and designed to be safe, instantly effective and inexpensive to allow for universal deployment in resource-poor counties.

It is estimated that 13-38% of all pregnant women in South Africa are HIV positive1. Current estimates indicate that 90% of HIV-positive women in resource-poor settings do not have access to antiretroviral (ARV) medication on a regular basis and often reject treatment due to fear of the stigma-related threats of violence and abandonment. In the absence of ARV treatment, a pregnant woman has a 14-42% chance of passing HIV on to their child during labour and delivery2. A higher HIV vaginal viral load in the mother is associated with an increased risk of transmission to their unborn child. Vitalwave™ is currently being designed to safely and immediately reduce the HIV vaginal viral load to low levels.

Read more »

Related Posts Plugin for WordPress, Blogger...

Staypressed theme by Themocracy